Alto Neuroscience, Inc.
ANRONYSE
$27.54
↑ +0.8%Jul 17 close · end-of-day
Price
1Y↑ +939.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$905.9M
Enterprise Value
$658.1M
P/E
—
P/S
—
P/B
3.7
EV/EBITDA
—
PEG
—
FCF Yield
-6.9%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$74.3M
Free Cash Flow (TTM)
-$62.9M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-30.5%
ROIC
—
Debt / Equity
0.1
Net Cash
$247.7M
Return 1Y
+856.3%
Company profile
We are a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto Neuroscience, Inc. was incorporated under the laws of the State of Delaware in March 2019. Our principal executive office is located at 369 South San Antonio Road, Los Altos, CA.
- CEO
- Amit Etkin
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- California
- Website
- www.altoneuroscience.com
Management & directors
- Etkin AmitPRESIDENT AND CEO
- Smith Nicholas ConradCHIEF FINANCIAL OFFICER & CBO
Roles derived from SEC Form 4 filings.
Earnings
ANRO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.80↑ +42.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$37.8M | -$68.6M | -$66.4M |
| Net income | -$36.3M | -$61.4M | -$63.2M |
| Diluted EPS | -$9.73 | -$2.50 | -$2.19 |
| Operating cash flow | -$33.4M | -$47.4M | -$51.8M |
| Free cash flow | -$33.9M | -$49.5M | -$51.8M |
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$18.3M | -$18.9M | -$17.0M | -$15.7M | -$18.7M | -$15.0M | -$17.1M | -$27.1M |
| Net income | -$16.0M | -$16.8M | -$15.2M | -$15.2M | -$17.7M | -$14.2M | -$16.2M | -$26.2M |
| Diluted EPS | -$0.60 | -$0.62 | -$0.52 | -$0.56 | -$0.65 | -$0.52 | -$0.46 | -$0.80 |
| Operating cash flow | -$11.7M | -$11.7M | -$13.0M | -$16.6M | -$13.8M | -$9.9M | -$11.5M | -$27.1M |
| Free cash flow | -$12.0M | -$12.7M | -$13.5M | -$16.6M | -$13.8M | -$9.9M | -$11.5M | -$27.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-14 | Etkin Amit· PRESIDENT AND CEO | Gift | 400,000 | $0.00 | $0.00 | filing |
| 2026-03-01 | Etkin Amit· PRESIDENT AND CEO | Tax withholding | 6,227 | $19.69 | $122,609.63 | filing |
| 2026-03-01 | Smith Nicholas Conrad· CHIEF FINANCIAL OFFICER & CBO | Tax withholding | 2,806 | $19.69 | $55,250.14 | filing |
Latest 3 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.